Develops therapies made from engineered cells for people with diabetes, B cell cancers, and B cell-mediated autoimmune diseases.
10-K for FY2025, filed Mar 3, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 3, 2026
10-Q for Q3 FY2026, filed Nov 5, 2026
$20.4MView ↗
A narrower pipeline
The earlier report described a broad pipeline spanning oncology, diabetes, central nervous system and genetic disorders, including allogeneic CAR T programs. The latest report centers on diabetes and B cell diseases, and says development of some allogeneic CAR T programs is suspended.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 3, 2026
Competes with AbbVie, Allogene Therapeutics, Aspect Biosystems, AstraZeneca, Bristol-Myers Squibb, Cabaletta Bio, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Eli Lilly, Gilead Sciences, Johnson & Johnson, Kelonia Therapeutics, Kyverna Therapeutics, Legend Biotech, Novartis, Roche, Umoja Biopharma, and Vertex Pharmaceuticals
10-K for FY2025, filed Mar 3, 2026Other companies have stated that they are developing cell and gene therapies that may address type 1 diabetes, oncology, and B cell…View ↗
Loading...